Literature DB >> 25943786

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

Jeffrey R Sawyer1, Erming Tian2, Christoph J Heuck2, Donald J Johann2, Joshua Epstein2, Charles M Swanson3, Janet L Lukacs3, Regina Lichti Binz3, Marian Johnson3, Gael Sammartino3, Maurizio Zangari2, Faith E Davies2, Frits van Rhee2, Gareth J Morgan2, Bart Barlogie2.   

Abstract

Multiple myeloma is a B-cell malignancy stratified in part by cytogenetic abnormalities, including the high-risk copy number aberrations (CNAs) of +1q21 and 17p(-). To investigate the relationship between 1q21 CNAs and DNA hypomethylation of the 1q12 pericentromeric heterochromatin, we treated in vitro peripheral blood cultures of 5 patients with balanced constitutional rearrangements of 1q12 and 5 controls with the hypomethylating agent 5-azacytidine. Using G-banding, fluorescence in situ hybridization, and spectral karyotyping, we identified structural aberrations and copy number gains of 1q21 in the treated cells similar to those found in patients with cytogenetically defined high-risk disease. Aberrations included 1q12 triradials, amplifications of regions juxtaposed to 1q12, and jumping translocations 1q12. Strikingly, all 5 patients with constitutional 1q12 rearrangements showed amplifications on the derivative chromosomes distal to the inverted or translocated 1q12 region, including MYCN in 1 case. At the same time, no amplification of the 1q21 region was found when the 1q12 region was inverted or absent. These findings provide evidence that the hypomethylation of the 1q12 region can potentially amplify any genomic region juxtaposed to it and mimic CNAs found in the bone marrow of patients with high-risk disease.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2015        PMID: 25943786      PMCID: PMC4463736          DOI: 10.1182/blood-2015-03-632075

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.

Authors:  Matthew W Jenner; Paola E Leone; Brian A Walker; Fiona M Ross; David C Johnson; David Gonzalez; Laura Chiecchio; Elisabet Dachs Cabanas; Gian Paolo Dagrada; Mathew Nightingale; Rebecca K M Protheroe; David Stockley; Monica Else; Nicholas J Dickens; Nicholas C P Cross; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

2.  Segmentation of human chromosomes induced by 5-ACR (5-azacytidine).

Authors:  E Viegas-Péquignot; B Dutrillaux
Journal:  Hum Genet       Date:  1976-12-15       Impact factor: 4.132

3.  DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors.

Authors:  Bodour Salhia; Angela Baker; Gregory Ahmann; Daniel Auclair; Rafael Fonseca; John Carpten
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

4.  Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Authors:  Hervé Avet-Loiseau; Michel Attal; Loic Campion; Denis Caillot; Cyrille Hulin; Gerald Marit; Anne-Marie Stoppa; Laurent Voillat; Marc Wetterwald; Brigitte Pegourie; Eric Voog; Mourad Tiab; Anne Banos; Jerome Jaubert; Didier Bouscary; Margaret Macro; Brigitte Kolb; Catherine Traulle; Claire Mathiot; Florence Magrangeas; Stephane Minvielle; Thierry Facon; Philippe Moreau
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

6.  The characterization of high-resolution G-banded chromosomes of man.

Authors:  J J Yunis; J R Sawyer; D W Ball
Journal:  Chromosoma       Date:  1978-08-14       Impact factor: 4.316

7.  Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q.

Authors:  Jeffrey R Sawyer; Guido Tricot; Janet L Lukacs; Regina Lichti Binz; Erming Tian; Bart Barlogie; John Shaughnessy
Journal:  Genes Chromosomes Cancer       Date:  2005-01       Impact factor: 5.006

Review 8.  Genetics and epigenetics of 1q rearrangements in hematological malignancies.

Authors:  A Fournier; A Florin; C Lefebvre; F Solly; D Leroux; M B Callanan
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

9.  5-Azacytidine-induced undercondensations in human chromosomes.

Authors:  M Schmid; T Haaf; D Grunert
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

Review 10.  IMWG consensus on risk stratification in multiple myeloma.

Authors:  W J Chng; A Dispenzieri; C-S Chim; R Fonseca; H Goldschmidt; S Lentzsch; N Munshi; A Palumbo; J S Miguel; P Sonneveld; M Cavo; S Usmani; B G M Durie; H Avet-Loiseau
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

View more
  16 in total

Review 1.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

2.  Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.

Authors:  Chutima Kunacheewa; Hans C Lee; Krina Patel; Sheeba Thomas; Behrang Amini; Samer Srour; Qaiser Bashir; Yago Nieto; Muzzaffar H Qazilbash; Donna M Weber; Lei Feng; Robert Z Orlowski; Pei Lin; Elisabet E Manasanch
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-01-15

Review 3.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

4.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Authors:  J R Sawyer; E Tian; J D Shaughnessy; J Epstein; C M Swanson; C Stangeby; C L Hale; L Parr; M Lynn; G Sammartino; J L Lukacs; C Stein; C Bailey; M Zangari; F E Davies; F Van Rhee; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

Review 5.  Interpretation of cytogenetic results in multiple myeloma for clinical practice.

Authors:  A M Rajan; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-10-30       Impact factor: 11.037

6.  MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.

Authors:  Chunyan Gu; Lang Feng; Hailin Peng; Hongbao Yang; Zhenqing Feng; Ye Yang
Journal:  Oncotarget       Date:  2016-01-26

7.  The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.

Authors:  Mohammad Alzrigat; Helena Jernberg-Wiklund
Journal:  RNA Dis       Date:  2017-04-03

8.  Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.

Authors:  Thomas Smol; Annika Dufour; Sabine Tricot; Mathieu Wemeau; Laure Stalnikiewicz; Franck Bernardi; Christine Terré; Benoît Ducourneau; Hervé Bisiau; Agnès Daudignon
Journal:  Mol Cytogenet       Date:  2017-07-01       Impact factor: 2.009

9.  [The correlations and prognostic value of neutrophil to lymphocyte ratio, immunophenotype and cytogenetic abnormalities in patients with newly diagnosed multiple myeloma].

Authors:  J J Hu; S M Nie; Y Gao; X S Yan; J X Huang; T L Li; S S Liu; C X Mao; J J Zhou; Y J Xu; W Wang; F J Meng; X Q Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

10.  The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability.

Authors:  Jennifer Derrien; Catherine Guérin-Charbonnel; Victor Gaborit; Loïc Campion; Magali Devic; Elise Douillard; Nathalie Roi; Hervé Avet-Loiseau; Olivier Decaux; Thierry Facon; Jan-Philipp Mallm; Roland Eils; Nikhil C Munshi; Philippe Moreau; Carl Herrmann; Florence Magrangeas; Stéphane Minvielle
Journal:  Genome Med       Date:  2021-08-09       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.